<DOC>
	<DOC>NCT00562458</DOC>
	<brief_summary>To evaluate Arimidex 6 month therapy as an adjuvant treatment in postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by tumoral response assessment.</brief_summary>
	<brief_title>Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Patients to be included in the program are that ones according to the indications specified in the Romanian anastrozole (Arimidex) approved SmPC (attached to the protocol)and who are already treated with anastrozole for at least 1 month before inclusion in this program/noninterventional study. Patients not to be included in the programme: patients who have a known hypersensitivity to anastrozole (ArimidexÂ®) or any of its excipients.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Advanced breast cancer in postmenopausal women</keyword>
</DOC>